Equities

VentriPoint Diagnostics Ltd

VentriPoint Diagnostics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.14
  • Today's Change0.00 / 0.00%
  • Shares traded425.37k
  • 1 Year change-6.67%
  • Beta0.7291
Data delayed at least 15 minutes, as of Nov 14 2024 20:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

  • Revenue in CAD (TTM)72.07k
  • Net income in CAD-5.02m
  • Incorporated2007
  • Employees--
  • Location
    VentriPoint Diagnostics Ltd18 Hook Ave, Unit 101TORONTO M6P 1T4CanadaCAN
  • Phone+1 (416) 848-4156
  • Fax+1 (416) 848-0709
  • Websitehttps://www.ventripoint.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cloud DX Inc2.07m-9.87m12.09m--------5.82-0.1052-0.10520.0222-0.2380.97111.238.32---461.80------89.94---475.56--0.0546-1.57----55.39--2.56------
H-Source Holdings Ltd679.97k-3.30m12.11m--------17.81-0.0281-0.02810.0058-0.05450.49610.495.07---241.05-300.92---1,550.0210.55---485.95-613.680.0134-2.61-----51.99--3.93------
Medx Health Corp388.64k-3.82m14.82m--------38.13-0.0171-0.01710.0017-0.0310.46510.58255.07---457.43-653.82----39.8149.55-983.43-736.740.0492-2.01-----10.68-15.9510.77------
Hydreight Technologies Inc13.94m-1.68m20.56m--------1.48-0.0439-0.04390.364-0.04735.3584.99227.43---64.39------40.39---12.04--0.4353------169.64--67.69------
NuGen Medical Devices Inc346.79k-7.63m21.77m12.00------62.78-0.0386-0.03860.0017-0.01720.04580.57625.08---100.85---152.05--49.15---2,201.37--0.1734-4.901.83--117.51---67.84------
VentriPoint Diagnostics Ltd.72.07k-5.02m22.60m--------313.56-0.032-0.0320.0005-0.01310.0316--0.4006---220.33-105.23-562.35-178.0148.0867.16-6,965.84-8,020.43---79.53-----27.86-3.960.0177------
Aurora Spine Corp23.66m-889.47k33.47m13.00--4.7959.431.41-0.0116-0.01160.30750.09081.481.894.89---5.56-16.00-8.18-22.2360.3946.65-3.76-11.761.38-2.570.4242---2.4010.83-11.93--10.36--
Data as of Nov 14 2024. Currency figures normalised to VentriPoint Diagnostics Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.